CTRI/2022/09/045600Not yet recruiting未知
A Randomised Controlled Trial of Fasting and Surgery Timing (FaST) in a tertiary care referral centre ââ?¬â?? Is it time for the ââ?¬Ë?Think Drinkââ?¬â?¢ campaign? - FaST
Mario Victor Newton0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients admitted for elective surgery.
- •(Operations were defined using the NCEPOD classification of surgical intervention. Elective operations were defined as intervention planned or booked in advance of routine admission to hospital. Timing tosuit patient, hospital and staff.)
Exclusion Criteria
- •Emergency cases, cases planned under local anesthesia, Diabetics, Chronic Liver Disease
Investigators
Similar Trials
Not yet recruiting
Phase 1
A Single-Dose study under fasting condition to assess the Bioequivalence of Etoricoxib 120 mg tablets (Test formulation), provided by DKSH (Thailand) Limited with a reference formulation Arcoxia® 120 mg tablets, in 24 healthy volunteersBioequivalence studyBioequivalenceEtoricoxibTCTR20181008002Bio-innova and Synchron.Co.,Ltd24
Not yet recruiting
Phase 1
A Single-Dose study under fasting condition to assess the Bioequivalence of Febuxostat 80 mg tablets (Test formulation), provided by DKSH (Thailand) Limited with a reference formulation Feburic(R) 80 mg tablets, in 32 healthy volunteersBioequivalence studyFebuxostatTCTR20200916003Bio-innova and Synchron.Co.,Ltd32
Completed
Not Applicable
Monocentric longitudinal Study to Fasting Effects on Energy and Bone MetabolismE66.9R63.2Obesity, unspecifiedPolyphagiaDRKS00004249KLinik Buchinger Bodensee GmbH55
Not yet recruiting
Unknown
Study to observe the safety of fasting and improvement in aging indices in healthy adultsJPRN-UMIN000052921Juntendo University80
Not yet recruiting
Phase 1
A single dose study under fasting condition to access the Bioequivalence of Etoricoxib 120 mg tablets (Test formulation), manufactured by Interthai Pharmaceutical Manufacturing Limited with a reference formulation Arcoxia® - MSD, in 24 healthy volunteersBioequivalence study in healthy volunteersBioequivalence,EtoricoxibTCTR20170201002Bio-innova and Synchron.Co.,Ltd24